In a report issued on February 26, Andrew Berens from Leerink Partners maintained a Hold rating on Puma Biotechnology (PBYI – Research Report), with a price target of $10.00. The company’s shares closed last Tuesday at $10.16.
According to TipRanks.com, Berens is a 4-star analyst with an average return of 12.7% and a 61.6% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Deciphera Pharmaceuticals.
Puma Biotechnology has an analyst consensus of Hold, with a price target consensus of $12.50.
The company has a one-year high of $14.14 and a one-year low of $5.50. Currently, Puma Biotechnology has an average volume of 495.8K.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PBYI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.